The study of the Access PTS treatment found that, on average, patients with post-thrombotic syndrome (PTS) experienced a decline in symptoms from severe to borderline mild.
Access PTS, which uses the Ekos therapy, met its primary efficacy endpoint and showed a significant improvement of Villalta Scores—a measure of disease specific to PTS—of 34% at 30 days across 77 limbs on 73 patients.
The trial showed that patients with PTS can be treated safely and effectively with the Ekos therapy and revealed a 21% improvement in their quality of life.
“Until now, most chronic DVT and PTS sufferers had no other treatment options," said Ekos vice president and general manager, Matt Stupfel.
The Ekos therapy uses ultrasonic waves and thrombolytic drugs to effectively dissolve blood clots and restore blood flow.
DVT occurs when a blood clot forms in the deep veins of the body, usually in the leg or pelvis, and limits blood flow. If the clot isn't dissolved within a few weeks, it can become a chronic DVT, which can permanently damage the valves in veins and create PTS.
Shares in BTG rose 0.82% in early trading.